Clinical Capital Conversations

FemTech is often framed as a market trend. In this episode of “Clinical Capital Conversations”, Dr. Peter M. Kovacs explains why it is actually a long-overdue clinical correction.Together with Roswitha Verwer, Founder and CEO of “YON E”, and Muskaan Bhan, Chief Clinical Officer, this conversation explores why women were historically excluded from clinical trials, how biased data still shape healthcare AI, and why continuous measurement is changing medicine.This episode is for investors, founders, and healthcare leaders who care about execution, responsibility, and long-term impact, not shortcuts.Timecode:00:00 Welcome and Introduction00:50 Progress and Achievements in FemTech02:16 Strategic Planning and Teamwork05:18 Challenges in FemTech and AI Development08:42 Importance of Continuous Data Tracking12:49 Ethical Considerations and Long-Term Goals16:20 FemTech Industry Trends and Future Outlook20:29 Navigating Advisory Roles in a Regulated Era20:48 The Rise of FemTech and Female Health Initiatives22:38 Building a Supportive FemTech Community23:19 Challenges in FemTech Investment24:34 Investor Conversations and Strategies30:21 The Importance of Team and Personal Connections33:08 Future Plans and Closing RemarksSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Roswitha Verwer LinkedIn: https://www.linkedin.com/in/roswitha-verwer-b2b636137/Roswitha Verwer Personal Website: https://www.roswithaverwer.com/Dr. Muskaan Bhan: https://www.linkedin.com/in/dr-muskaan-bhan-9b7123120/

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs sits down with Roswitha Verwer (YONE) and Karoly Szanto to unpack what most investors miss in early-stage health innovation: execution is the moat.YONE delivered the majority of a 12-month roadmap in 6 months. We break down how it happened, what systems made it possible, and why femtech fundraising is still biased even when the operating metrics are strong.What we cover:How to build vendor communication into contracts and timelinesRunning a high-performance global team without losing controlMeritocracy, KPIs, and having hard performance conversations with factsWhy female founders and femtech still face access barriers to capitalThe gap stage problem in medtech funding, and why value-driven partners matterWhy many accelerators create noise, not outcomesThe next milestones for YONE, including the 600,000 co-investment raise and the seed round planThis is a conversation for investors, founders, and operators who want clinical innovation that scales, de-risks, and reaches patients.Timecode:00:00 Introduction and Welcome00:21 Achievements and Progress01:38 Lessons for Startup Founders02:56 Building a Strong Global Team04:44 Handling Underperformance09:36 Future Challenges and Milestones13:28 Fundraising Challenges for FemTech27:36 The Importance of Value-Driven Partnerships31:29 Conclusion and GratitudeSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Roswitha Verwer: https://www.linkedin.com/in/roswitha-verwer-b2b636137/Károly Szántó: https://www.linkedin.com/in/karolyszanto1/

This is a continuation of our main conversation on what it takes to turn medical innovation into scalable impact.In this episode, Dr. Peter M. Kovacs sits down with Károly Szántó and Thijmen Meijer to unpack the co-investor question that determines everything in biotech and medtech.If you are building or funding early-stage life sciences, this is the uncomfortable truth: the cap table is a governance system. The wrong co-investors can slow execution, distort milestones, and burn capital. The right co-investors create speed, trust, and real de-risk.What we cover:Why investor labels matter less than incentives and behaviorSkin in the game, and why it changes decision qualityTwo co-investor archetypes that create real synergyHow family offices think, and why relationships and values come firstEurope versus Asia: differences in investor mindset and cultureWhy smaller, domain-specific funds are gaining momentumPractical questions founders and investors should ask before partneringWho this is for: Founders in biotech and medtech, healthcare VCs, family offices, corporate venture teams, private equity, and operators building clinical infrastructure.Timecode:00:00 Introduction to Key Stakeholders00:22 Types of Co-Investors01:09 Value Proposition and Commitment02:10 Investor Specialization and Synergies03:26 Role of Angel Investors04:02 Corporate Venture Capital04:44 Family Offices and Personal Touch08:56 Challenges in Different Regions09:32 Building Relationships with Investors10:34 High Net Worth Individuals18:02 Micro Funds and Emerging Managers19:51 Conclusion and Future OutlookSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Károly Szántó: https://www.linkedin.com/in/karolyszanto1/Thijmen Meijer: https://www.linkedin.com/in/thmnmr/UniPrisma: https://uniprisma.com/

Europe has elite science. Asia has a capital. So why do so many European university spinouts never reach venture readiness or exits?In this episode, Dr. Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer about the real gaps that block deep tech startups, especially in Central and Eastern Europe, and what a modern support model looks like.What we cover:Why most spinouts never become VC fundableThe commercialization gap between research and marketsMindset, team design, and why the founder is not always the CEOIP clarity and why it is the first gate to investabilityMilestones that remove ambiguity and build investor trustSmart money versus dumb money in biotech and medtechHow to bridge Europe’s science with Asia’s capital through operators and partnershipsKey takeaway: funding is not the goal. Value creation is the goal.Subscribe for more conversations at the crossroads of science and capital.Timecode:00:00 Introduction and Meeting the Guests00:16 Challenges Faced by European Startups04:44 The Importance of Mindset in Commercialization07:43 Building Effective Teams for Startups14:04 Investment Challenges and Opportunities17:15 The Role of Clear Goals and Milestones21:40 The Investor's Perspective25:26 Introduction to Portfolio Companies25:45 The Need for New Investment Models26:05 Technological Boom and Efficiency26:29 Building Companies for Impact27:30 Challenges in Deep Tech Investment27:50 Value-Driven Founders29:12 Operational Models and Risk Mitigation30:50 Identifying Good Partners32:55 Scaling Up and Future Goals33:43 Investor and Founder Dynamics37:09 Cultural Differences in Startups46:40 Lab Space and Resource Challenges49:39 Networking and Collaboration51:57 Preparing for Global MarketsSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Károly Szántó: https://www.karolyszanto.com/Thijmen Meijer: https://www.thijmenmeijer.com/UniPrisma: https://uniprisma.com/

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs speaks with Károly Szántó about venture studios, calculated risk, and what it really takes to turn promising innovation into execution.We cover:How a non-linear career becomes a competitive advantageWhy focus beats speed in early-stage venture buildingThe difference between high risk and calculated riskWhat university spinouts are missing, and how to fix it through market partnershipHow ecosystems change through examples, not speechesWhat investors should do diligence to avoid science-driven capital burnSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Timecode:00:00 Introduction and Guest Welcome00:26 Karoly's Career Journey01:16 Discovering Sales and Business Development03:46 Embracing Entrepreneurship07:55 Building Uni Prisma Venture Studio08:49 Venture Capital Experience13:57 Focus on Healthcare and Impact18:09 Challenges and Future Vision22:49 Conclusion and Final ThoughtsSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Károly Szántó: https://www.linkedin.com/in/karolyszanto1/

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Michaela Hrdlickova about Age Management and why workforce execution risk is one of the most overlooked variables in healthcare investing.We explore how work ability is measured, why leadership quality drives performance, and how investors can protect long-duration returns by treating human capital as infrastructure.This conversation is essential for biotech founders, healthcare investors, board members, and operators navigating long clinical timelines and execution complexity.Subscribe for more conversations at the crossroads of science and capital.Timecode:00:00 Introduction to Misa Hrdlickova and Age Management00:41 The Concept and History of Age Management03:01 Implementing Age Management in Companies05:50 Solutions and Processes for Age Management14:07 Misa Hrdlickova's Background and Career Journey21:24 Advice for Future Generations23:09 Conclusion and Final ThoughtsSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Michaela Hrdlickova: https://www.michaelahrdlickova.eu/Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Ales Vavra, a former hedge fund manager known for exposing weaknesses in overhyped biotech companies. Together, they explore what investors often misunderstand about biotech risk, why due diligence fails, how AI is reshaping investment analysis, and the mindset required to survive the volatility of the sector.If you invest in biotech, medtech, or clinical infrastructure, this conversation will challenge your assumptions and sharpen your thinking.Topics covered:• The psychology that misleads biotech investors• Why execution risk matters more than scientific novelty• How AI can support diligence without replacing expertise• The danger of hype cycles in Alzheimer’s, longevity, and obesity• Why diversification and discipline outperform intuition• What separates resilient investors from speculative gamblersSubscribe to Clinical Capital Conversations for more insights at the intersection of science and capital.Timecode:00:00 Introduction and Guest Background01:44 Investment Strategies in Healthcare03:13 Red Flags in Healthcare Investments06:04 Role of AI in Investment Decisions08:16 Advice for Healthcare Investors12:01 Success Stories and Challenges14:07 The Role of Sugar in Our Lives14:55 Alcohol Consumption and Life Balance15:43 The Hype and Reality of AI18:40 Investment Challenges for Startups21:48 Bitcoin and Long-Term Value25:15 Personal Reflections and Future Outlook26:17 Final Thoughts on Investment and LifeSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Ales Vavra https://www.linkedin.com/in/ales-vavra-6423475/Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

AI memory therapy is no longer a concept. It is here, clinically validated, and already helping dementia patients feel less lonely and more connected.In this episode of Clinical Capital Conversations, Peter M. Kovacs speaks with Kompanion Care founder Peter Markus about Lilia, an AI-powered therapeutic platform that combines reminiscence therapy, family-generated memories, and digital biomarkers to deliver real clinical impact.We explore:How personal loss shaped the companyWhy AI can scale proven psychotherapiesHow clinical validation creates trustWhy reimbursement is the true growth pathHow digital biomarkers will transform early detectionIf you want to understand where dementia care, digital therapeutics, and AI-driven monitoring are heading, this conversation is essential.Timecode:00:00 Introduction and Guest Introduction00:23 Peter Markus's Background and Career Journey01:26 The Birth of Kompanion Care04:31 Innovative Technology Behind Lilia Platform11:41 Challenges and Importance of Medical Software15:23 Current Progress and Future Plans22:17 Investment and Market Strategy37:28 Conclusion and Final ThoughtsSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Péter Márkus: https://www.linkedin.com/in/pmarkus/Kompanion Care: https://www.kompanioncare.com/

Inside Europe, a new type of hospital is emerging. In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter sit down with Antonín Hlavinka, the innovation and digitalization lead at University Hospital Olomouc. Together, explore how one of the largest hospitals in the Czech Republic built a functioning AI ecosystem that is delivering measurable clinical impact today.Discuss certified and experimental clinical AI tools, governance structures, telemedicine innovation, multimodal prediction engines, and real patient cases where AI detected what humans could not. This conversation highlights what investors, clinicians, and health system operators need to understand as Europe moves toward agent-driven hospital environments.If you want a front-row look at the future of digital healthcare, this episode is essential.Timecode:00:00 Welcome and Introduction00:24 Role and Responsibilities in Healthcare01:31 Adoption of AI in Healthcare02:27 Impact of COVID-19 on Technology Adoption04:18 AI Applications in Hospitals04:49 Certified vs. Experimental AI Models07:47 AI Tools in Use14:05 Innovation and Project Management21:41 Introduction to AI in Radiology22:10 The Evolution of AI in Healthcare22:55 Challenges and Rapid Developments23:30 Microsoft's Game-Changing AI Model24:42 AI in Medical Practice27:41 AI in Education28:55 Balancing AI and Human Cognition30:55 AI's Impact on Healthcare Workforce33:30 Global Perspectives on AI Adoption36:42 Future of AI in Hospitals39:03 Collaborating with Startups and Innovators40:33 Conclusion and Future ProspectsSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Antonín Hlavinka: https://www.linkedin.com/in/anton%C3%ADn-hlavinka-b045754b/Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

Can artificial intelligence bring us closer instead of pulling us apart?In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs and Pavlina Walter speak with Vassili Le Moigne, founder of InTouch, about how AI voice technology is transforming elder care across 89 countries.Together, they explore how scalable empathy, data ethics, and thoughtful design can redefine how we care for aging populations without losing the human touch.Topics covered:The origin of InTouch and its mission to reduce lonelinessVoice AI and cognitive engagement for seniorsGDPR, data ethics, and protecting user trustThe economics of aging and independent livingThe business of empathy in global health innovationTimecode:00:00 Starting the Call: A Busy Morning03:00 Introducing Vassili: Background and Journey04:51 The Birth of InTouch: Inspiration and Development08:07 How InTouch Works: Features and Benefits10:46 Global Reach and Compliance16:47 Real-Life Impact: Testimonials and Feedback19:36 Different Approaches for Alzheimer's Patients21:06 Future Plans and Global Expansion22:45 Addressing Loneliness Beyond Seniors23:47 Technical Challenges and Solutions24:55 Ethical Choices in Voice Selection25:28 Market Differences: Europe vs. USA27:58 Cultural Insights and Language Adaptations30:36 Mentoring and Advice for Startups34:17 Concluding Thoughts on InTouchSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Vassili Le Moigne: https://www.linkedin.com/in/vassililemoigne/Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

Biologics are transforming medicine, but who’s enabling that transformation behind the scenes? In this episode, I sit down with Jiri Raska, Chief Commercial Officer at Quinta Analytica, and Pavlina Walter, to discuss:Why biologics and biosimilars are now the fastest-growing segment in pharmaHow CROs are evolving from vendors to strategic partnersWhat small biotechs need most to reach clinical milestonesEurope’s regulatory turnaround under the new CTIS systemThe rise of ADCs and how integrated analytics create real competitive advantageTimecode:00:00 Introduction to Jiri and Quinta Analytica01:09 Jiri's Background and Passion for Chemistry01:56 Transition to Business Development03:43 Current Trends in Biologics and Biosimilars05:57 Challenges and Opportunities in Clinical Studies09:17 Supporting Small Biotech Startups13:08 Customer Success Management14:47 Expansion and Collaboration16:43 Future of Personalized Medicine19:26 Regulatory Challenges in Europe23:58 Ostrava Subsidiary and Cross-Border Recruitment27:00 Future Directions for Quinta Analytica29:50 Jiri's Personal Career Aspirations31:49 Conclusion and Final ThoughtsSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Jiri Raska: https://www.linkedin.com/in/jiri-raska-pharma/Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

In this episode of Clinical Capital Conversations, I sat down with Pavlina Walter and our guest Jiri Pavlíček, a mentor, entrepreneur, and one of Central Europe’s most respected MedTech leaders. Together, we explored everything from the European MedTech landscape to AI-driven diagnostics, MDR regulation, and the importance of risk-taking culture. From navigating post-Communist transitions to leading a multi-market MedTech enterprise and embracing AI-driven technologies, Jiri’s story reveals what it takes to combine operational excellence with human-centered values.Key themes:Leadership and values in healthcare innovationEuropean MedTech market outlook and MDR challengesAI as the next wave in diagnosticsBuilding teams and trust that scaleResilience, mindset, and long-term impactTimecode:00:00 Welcome and Introduction00:28 Jiri's Background and Early Life01:26 Professional Journey and Achievements03:49 Founding Aspironix and Business Insights06:05 Current MedTech Landscape and Challenges11:58 AI in Medical Devices14:19 Personal Reflections and Future Goals17:04 Advice for Startups and Entrepreneurs19:29 Closing RemarksSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Jiri Pavlicek: https://www.linkedin.com/in/jiri-pavlicek-7b32b12/Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

In this episode, Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer, co-founders of Uniprisma, about how Central Europe’s startup scene is maturing from ideas to execution.They discuss founder psychology, team readiness, ego management, and why venture studios are redefining early-stage investment across Europe.Chapters00:00  Introduction and context01:10  What Uniprisma is and how it started05:30  Why founder personality defines success09:15  When to replace the founder as CEO14:20  Building high-performance startup teams18:40  The biggest mistakes in early-stage ventures23:00  Teaching founders to engage markets early28:15  Investor perspective on people vs products33:30  The YON E Health case and early success stories38:50  How venture studios de-risk early investment44:00  Central Europe’s innovation potential49:30  Final reflectionsIf you invest in early-stage ventures or build founder support ecosystems, watch this conversation to understand how execution discipline is becoming Central Europe’s competitive edge.Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.Links:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/Guests:Károly Szántó: https://www.linkedin.com/in/karolyszanto1/Thijmen Meijer: https://www.linkedin.com/in/thmnmr/

In this episode, Peter M. Kovacs speaks with Roswitha Verwer and Dr. Muskaan Bhan, the founders of YON E Health, about transforming personal trauma into global innovation. They discuss the journey from idea to clinical-grade Femtech, data ethics, diversity in research, and why women’s health is the next major frontier for investors and operators alike.Chapters00:00  Introduction and context01:15  How Roswitha and Muskaan met04:30  The personal story behind YON E Health08:10  What pH and temperature tell us about women’s health12:25  Building a medical device from concept to clinical validation18:40  Why diversity in clinical data matters23:00  Regulatory roadmap and CE/FDA pathway27:30  Investment challenges for female founders33:00  Data privacy, consent, and trust39:45  Culture, education, and global adoption45:20  Team building and advisory governance52:10  The future of Femtech and Peter’s reflectionsIf you are investing in healthcare or building within Femtech, watch this discussion to understand why precision, transparency, and inclusion are the new performance metrics.Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital.

What will decide the future of AI in Europe: ethics, bureaucracy, or competitiveness?In this episode, I sit down with Jan Kavalírek, Deputy Minister of Industry and Trade and Government Envoy for AI in the Czech Republic, together with Pavlina Walter, to discuss:Why Czechia was the first EU country to propose AI simplification.How regulation can protect safety without paralysing innovation.What Europe must do to close the gap with the US and China.The role of startups and SMEs in building a competitive AI ecosystem.Why AI policy directly impacts healthcare, clinical research, and patient outcomes.Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital.Timecode:00:00 Introduction to Jan Kavalirek and His Role00:52 Goals and Ambitions for AI in Czechia and EU01:38 Simplifying AI Legislation in the EU03:16 Challenges and Support for AI Providers07:05 Collaboration and Competitiveness in AI12:25 Personal Reflections and Experiences18:10 Future Prospects and ConclusionLinks:Jan Kavalírek : linkedin.com/in/jan-kavalirek-339a1a298Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/

Who We Are: PMK Group and Our Mission in Biotech | Clinical Capital ConversationsBiotech often fails for the wrong reasons. Nearly 60% of clinical trial failures are due to technical execution, not the science itself.In this episode, Dr. Peter M. Kovacs explains why he founded PMK Group, a firm that combines capital with clinical and regulatory expertise to reduce technical failures and accelerate drug development.Why it matters:– Billions are lost to preventable execution failures– Patients wait years for therapies that could be delivered faster– Investors face unnecessary downside riskPMK Group’s model is different: we do not just invest money. We invest experience, systems, and execution.Subscribe to Clinical Capital Conversations for more insights at the crossroads of science and capital.Timecode:00:00 Introduction to Success in Biotech00:16 Understanding the Main Risks in Biotech00:44 Meet the Leader: Peter M. Kovacs01:06 The PMK Group Difference01:42 Minimizing Technical Failures02:09 Supporting Biotech and MedTech Companies02:32 Vision for the Future02:58 Call to CollaborateLinks:Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/Peter M. Kovacs Personal Website:https://www.petermkovacs.com/PMK Group Website: https://www.pmk-group.com/

What does real AI adoption in healthcare look like when you leave the hype behind? In this Prague Episode, I speak with Lukas Benzel, Managing Director of the Czech Association of Artificial Intelligence, and Pavlina Walter. We cover hospital adoption, the shift from sick care to prevention, the role of AI in clinical trials, Europe’s strategic approach, and why Singapore’s model is significant. Practical playbooks for investors, founders, and operators.Chapters 00:00 Welcome and context in Prague 00:35 Who is the Czech AI Association and why it matters 02:10 Hype vs value in AI adoption 04:05 Workshops, education, and finding business value 05:10 Sectors with traction: healthcare, education, defense, public sector 06:20 Health tech in Czech hospitals and regulation reality 07:55 Europe, US, and Asia: where to compete 09:10 Singapore lessons and the AI hub model 12:05 Constraints in hospitals: money, people, data readiness 13:00 Beyond radiology: prevention, trials, and operations 15:10 Patient acceptance, trust, and education 18:05 National AI strategy and public sector adoption 20:05 From basic research to new materials and drugs 21:30 AI for SMEs: pick use cases with ROI 23:00 Is AI a bubble. Why the answer is no 24:15 Productivity, new work, and personal tools 28:40 Cybersecurity and responsible use 31:00 Why an AI association, how to joinSubscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

In this episode, Dr. Peter M. Kovacs shares the story of how a study trip in 2018 transformed his life. Within weeks, he decided to relocate his family to Singapore, a country that would become both his home and the strategic hub for his global healthcare and investment ventures.Why Singapore? A clean, safe, efficient environment A business, biotech, and financial hub Access to Asia’s fast-growing healthcare markets Supportive policies and an innovation-friendly cultureThis is more than a relocation story. It’s about resilience, vision, and what it means to position yourself at the heart of the world’s most dynamic region.Timecode:00:00 Why and How I Moved to Singapore00:04 Starting My Healthcare MBA Journey00:56 Discovering Singapore01:27 Making the Move Permanent01:45 Professional and Personal Benefits of Singapore02:07 Expanding into the Asian Market03:20 Singapore: The Ideal Business HubLinks:LinkedIn: https://www.linkedin.com/in/petermkovacs/PMK Group Website: https://www.pmk-group.com/Peter M. Kovacs Personal Website: https://www.petermkovacs.com/